Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This is a non-randomized, phase II, open label study. The purpose of this study is to
estimate Progression Free Survival (PFS) after treatment with Peptide Receptor Radionuclide
Therapy (PRRT) 177Lu-DOTATOC standard dose (up to 4x7,4GBq 177Lu DOTATOC) in combination with
capecitabine (CAP) and temozolomide (TEM) - CAPTEM.
Patients with advanced, non-resectable and/or progressive gastro-entero-pancreatic
neuroendocrine tumors, GEP-NET, (G1, G2), in selected cases with high proliferation index
(Ki-67> 20%, usually below 55%), NETG3, with overexpression of somatostatin receptor (SSTR
positive) will be enrolled in the study.
Phase:
Phase 2
Details
Lead Sponsor:
University of Warmia and Mazury
Collaborators:
Maria Sklodowska-Curie Institute - Oncology Center Medical University of Warsaw National Center for Research and Development, Poland The Diagnostic and Therapeutic Center Gammed; Poland The Medical University of Warsaw; Poland